Introduction: While waiting for the development of specific antiviral therapies and vaccines to effectively neutralize the SARS-CoV2, a relevant therapeutic strategy is to counteract the hyperinflammatory status, characterized by an increase mainly of interleukin (IL)-1β, IL-2, IL-6, IL-7, IL-8, and tumor necrosis factor (TNF)-α, which hallmarks the most severe clinical cases. ‘Repurposing’ immunomodulatory drugs and applying clinical management approved for rheumatic diseases represents a game-changer option. In this article, we will review the drugs that have indication in patients with COVID-19, including corticosteroids, antimalarials, anti-TNF, anti-IL-1, anti-IL-6, baricitinib, intravenous immunoglobulins, and colchicine. The PubMed, Medline, and Cochrane Library databases were searched for English-language papers concerning COVID-19 treatment published between January 2020 and October 2020. Results were summarized as a narrative review due to large heterogeneity among studies. In the absence of specific treatments, the use of immunomodulatory drugs could be advisable in severe COVID-19 patients, but clinical outcomes are still suboptimal. An early detection and treatment of the complications combined with a multidisciplinary approach could allow a better recovery of these patients.
【저자키워드】 COVID-19, SARS-CoV2, Pneumonia, HCQ, anti-IL-6 drugs, 【초록키워드】 Treatment, Necrosis, antiviral therapy, Vaccine, Baricitinib, Corticosteroids, IL-6, immunoglobulins, drug, database, heterogeneity, Clinical outcome, IL-8, Complication, Clinical management, Colchicine, patients, therapeutic strategy, IL-2, IL-7, rheumatic disease, intravenous, anti-TNF, severe COVID-19 patients, Cochrane Library, hallmark, while, hyperinflammatory status, approach, neutralize, anti-IL-6, anti-IL-1, Result, approved, characterized, searched, absence, concerning, immunomodulatory drug, patients with COVID-19, 【제목키워드】 drug,